英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
---|---|---|---|---|---|---|
INCB024360
|
914471-09-3 |
4-氨基-N-(3-氯-4-氟苯基)-N'-羟基-1,2,5-恶二唑-3-甲脒
|
4-氨基-N-(3-氯-4-氟苯基)-N'-羟基-1,2,5-恶二唑-3-甲脒;CS-1034;INCB-024360;INCB 024360;INCB-24360;INDOLEAMINE-2;3-DIOXYGENASE INHIBITOR INCB024360;(E)-4-氨基-N-(3-氯-4-氟苯基)-N'-羟基-1,5-二唑-3-甲脒;INCB 024360 类似物;INCB024360 ANALOGUE;IDO5L;INCB024360 500MG;(E)-4-氨基-N'-(3-氯-4-氟苯基)-N-羟基-1,5-恶二唑-3-甲脒
|
C9H7ClFN5O2 |
271.6355832 | |
(Z)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboxamidine
|
1204669-58-8 |
艾卡哚司他
|
INCB024360;INCB-024360;INCB 024360;INCB-24360(INCB-024360);[C(Z)]-4-[[2-[(氨基磺酰基)氨基]乙基]氨基]-N-(3-溴-4-氟苯基)-N'-羟基-1,2,5-恶二唑-3-甲脒;艾卡哚司他
|
C11H13BrFN7O4S |
438.2328232 | |
Imatinib Mesylate
|
220127-57-1 |
甲磺酸伊马替尼
|
GLIVEC; CGP-57148B; STI-571;伊马替尼 甲磺酸酯;甲磺酸伊马替尼;伊马替尼 / 甲磺酸伊马替尼;IMA锡IB甲磺酸盐;甲磺酸伊马替你;甲磺酸伊马替尼99%;甲苯磺酸伊马替尼;甲磺酸伊马替尼
|
C30H35N7O4S |
589.71 | 606-892-3 |
GW843682X
|
660868-91-7 |
3-[2-(三氟甲基)苄氧基]-5-(5,6-二甲氧基-1H-苯并[D]咪唑-1-基)-2-噻吩甲酰胺
|
3-[2-(三氟甲基)苄氧基]-5-(5,6-二甲氧基-1H-苯并[D]咪唑-1-基)-2-噻吩甲酰胺;GW843682X;GW 843682X;GW843682;GW-843682X
|
C22H18F3N3O4S |
477.461 | 200-258-5 |
GSK J4 Hydrochloride
|
1373423-53-0 |
N-[2-(2-吡啶基)-6-(1,2,4,5-四氢-3H-3-苯并氮杂卓-3-基)-4-嘧啶基]-BETA-丙氨酸乙酯
|
CS-1667;N-[2-(2-吡啶基)-6-(1,2,4,5-四氢-3H-3-苯并氮杂卓-3-基)-4-嘧啶基]-BETA-丙氨酸乙酯;GSK J4 游离(检测J4溶样不要用甲醇,会发生酯交换);CS-2143;GSK J4 游离(检测J4溶样不要用甲醇,会发生酯交换)
|
C24H27N5O2 |
417.50348 | |
GSK J1
|
1373422-53-7 |
N-[2-(2-吡啶基)-6-(1,2,4,5-四氢-3H-3-苯并氮杂卓-3-基)-4-嘧啶基]-BETA-丙氨酸
|
N-[2-(2-吡啶基)-6-(1,2,4,5-四氢-3H-3-苯并氮杂卓-3-基)-4-嘧啶基]-BETA-丙氨酸;GSK J1(锂盐);CS-2305
|
C22H23N5O2 |
389.45032 | 200-258-5 |
4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol
|
937174-76-0 |
4-[2-(4-氨基-1,2,5-恶二唑-3-基)-1-乙基-7-[(3S)-3-哌啶基甲氧基]-1H-咪唑并[4,5-C]吡啶-4-基]-2-甲基-3-丁炔-2-醇
|
CS-37;4-[2-(4-氨基-1,2,5-恶二唑-3-基)-1-乙基-7-[(3S)-3-哌啶基甲氧基]-1H-咪唑并[4,5-C]吡啶-4-基]-2-甲基-3-丁炔-2-醇;GSK690693;GSK-690693;GSK 690693;GSK 690693;GSK-690693
|
C21H27N7O3 |
425.48 | |
GSK-650394
|
890842-28-1 |
2-环戊基-4-(5-苯基-1H-吡咯并[2,3-B]吡啶-3-基)苯甲酸
|
2-环戊基-4-(5-苯基-1H-吡咯并[2,3-B]吡啶-3-基)苯甲酸
|
C25H22N2O2 |
382.45438 | |
GSK1120212 (JTP-74057, Trametinib)
|
871700-17-3 |
曲美替尼
|
N-[3-[3-环丙基-5-[(2-氟-4-碘苯基)氨基]-3,4,6,7-四氢-6,8-二甲基-2,4,7-三氧代吡啶并[4,3-D]嘧啶-1(2H)-基]苯基]乙酰胺;曲美替尼 GSK220212;曲美替尼游离碱;N-[3-[3-环丙基-5-[(2-氟-4-碘苯基)氨基]-3,4,6,7-四氢-6,8-二甲基-2,7-三氧代吡啶并[4,3-D]嘧啶-1(2H)-基]苯基]乙酰胺;JTP-74057,GSK212,TRAMETINIB;曲美替尼;曲美替尼胶囊;CS-30;曲美替尼杂质
|
C26H23FIN5O4 |
615.3947932 | |
GNF 2
|
778270-11-4 |
3-[6-[[4-(三氟甲氧基)苯基]氨基]-4-嘧啶基]苯甲酰胺
|
GNF2;GNF 2;3-[6-[[4-(三氟甲氧基)苯基]氨基]-4-嘧啶基]苯甲酰胺;3-(6-(4-(TRIFLUOROMETHOXY)PHENYLAMINO)PYRIMIDIN-4-YL)BENZAMIDE
|
C18H13F3N4O2 |
374.321 | 200-256-5 |
GDC-0980 (RG7422)
|
1032754-93-0 |
(S)-1-[4-[[2-(2-氨基嘧啶-5-基)-7-甲基-4-(吗啉-4-基)噻吩并[3,2-D]嘧啶-6-基]甲基]哌嗪-1-基]-2-羟基丙-1-酮
|
(S)-1-[4-[[2-(2-氨基嘧啶-5-基)-7-甲基-4-(吗啉-4-基)噻吩并[3,2-D]嘧啶-6-基]甲基]哌嗪-1-基]-2-羟基丙-1-酮;GDC-0980,一种有效的 PI3K 抑制剂
|
C23H30N8O3S |
498.61 | |
GDC-0879
|
905281-76-7 |
2,3-二氢-5-[1-(2-羟基乙基)-3-(4-吡啶基)-1H-吡唑-4-基]-1H-茚-1-酮肟
|
GDC0879;GDC 0879;CS-187;2,3-二氢-5-[1-(2-羟基乙基)-3-(4-吡啶基)-1H-吡唑-4-基]-1H-茚-1-酮肟
|
C19H18N4O2 |
334.377 | |
GANT61
|
500579-04-4 |
2,2'-[[二氢-2-(4-吡啶基)-1,3(2H,4H)-嘧啶二基]二(亚甲基)]二[N,N-二甲基苯胺]
|
CS-867;GANT61;GANT-61;NSC 136476;GANT 61;2,2'-[[二氢-2-(4-吡啶基)-1,3(2H,4H(-嘧啶二基]二(亚甲基)]二[N,N-二甲基苯胺;2,N-二甲基苯胺];GANT61;GANT 61;NSC 136476
|
C27H35N5 |
429.61 | |
GO6983
|
133053-19-7 |
3-[1-[3-(二甲基氨基)丙基]-5-甲氧基-1H-吲哚-3-基]-4-(1H-吲哚-3-基)-1H-吡咯-2,5-二酮
|
3-[1-[3-(二甲基氨基)丙基]-5-甲氧基-1H-吲哚-3-基]-4-(1H-吲哚-3-基)-1H-吡咯-2,5-二酮;CS-674;GOE 6983;GO6983 GO-6983;GO 6983
|
C26H26N4O3 |
442.516 | |
fluconazole
|
86386-73-4 |
氟康唑
|
氟康唑-D4;氟康唑,大扶康;氟康唑;福司氟康唑杂质A;氟康唑(标准品);FLUCONAZOLE 氟康唑;氟康唑溶液,100PPM;氟康唑;大扶康;麦尼芬;麦道氟康;2-(2,4-二氟苯基)-1,3-双(1H-1,2,4-三唑-1-基)-2-丙醇;2-(2,4-三唑-1-基)-2-丙醇;Α-(2,4-二氟苯基)-Α-(1H-1,4-三唑-1-基甲基)-1H-1,4-三唑-1-基乙醇;2-(2,4-三氮唑-1-基)-3-丙醇
|
C22H24N2O8.C13H12N6OF2 |
750.70534 | 627-806-0 |
fingolimod hydrochloride
|
162359-56-0 |
盐酸芬戈莫德
|
鞘氨醇;芬戈莫德(FTY-720);盐酸芬戈莫德(FTY-721);芬戈莫德盐酸;芬戈莫德盐酸盐;苏戈莫德杂质
|
C19H33NO2.HCL |
343.93 | 680-631-1 |
FG-4592
|
808118-40-3 |
罗沙司他
|
N-[(4-羟基-1-甲基-7-苯氧基-3-异喹啉)羰基]甘氨酸;FG4592 N-[(4-羟基-1-甲基-7-苯氧基-3-异喹啉)羰基]甘氨酸;洛度司他;甘氨酸,N-[(4-羟基-1-甲基-7-苯氧基-3-异喹啉基)羰基]-;罗沙司他;FG-4592; 2-(4-HYDROXY-1-METHYL-7-PHENOXYISOQUINOLINE-3-CARBOXAMIDO)ACETIC ACID;N-[(4-羟基-1-甲基-7-苯氧基-3-异喹啉基)羰基]甘氨酸;CS-185
|
C19H16N2O5 |
352.34074 | 813-400-2 |
N4-(4-Phenoxyphenethyl)quinazoline-4,6-diamine
|
545380-34-5 |
N4-[2-(4-苯氧基苯基)乙基]-4,6-喹唑啉二胺
|
QNZ (EVP4593);EVP-4593;6-氨基-4-(4-苯氧基苯基乙基氨基)喹唑啉;CS-902;EVP4593;EVP 4593;EVP-4593;N4-[2-(4-苯氧基苯基)乙基]-4,6-喹唑啉二胺
|
C22H20N4O |
356.42 | |
EPZ-6438
|
1403254-99-8 |
EPZ6438
|
EPZ6438;EPZ 6438;E-7438;TAZEMETOSTAT;EPZ6438;EPZ 6438;E-7438;CS-971;N-[(1,2-二氢-4,6-二甲基-2-氧代-3-吡啶基)甲基]-5-[乙基(四氢-2H-吡喃-4-基)氨基]-4-甲基-4'-(4-吗啉基甲基)-[1,1'-联苯]-3-甲酰胺;EPZ-6438(E7438);CPDB1064;N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-基)氨基)-4-甲基-4'-(吗啉-4-基甲基)-[1,1'-联苯]-3-甲酰胺
|
C34H44N4O4 |
572.73756 | |
EHop-016
|
1380432-32-5 |
EHOP-016;N4-(9-ETHYL-9H-CARBAZOL-3-YL)-N2-(3-MORPHOLIN-4-YL-PROPYL)-PYRIMIDINE-2,4-DIAMINE
|
EHOP-016;N4-(9-ETHYL-9H-CARBAZOL-3-YL)-N2-(3-MORPHOLIN-4-YL-PROPYL)-PYRIMIDINE-2,4-DIAMINE;N4-(9-乙基-9H-咔唑-3-基)-N2-[3-(4-吗啉基)丙基]-2,4-嘧啶二胺;EHOP 016;EHOP016
|
C25H30N6O |
430.5453 | -0 |